Alcendor Donald J
Center for AIDS Health Disparities Research, Department of Microbiology, Immunology and Physiology, School of Medicine, Meharry Medical College, Nashville, TN 37208, USA.
J Clin Med. 2020 May 15;9(5):1490. doi: 10.3390/jcm9051490.
Alzheimer's disease (AD) is a progressive neurodegenerative disease that is the most common cause of dementia, especially among aging populations. Despite advances in AD research, the underlying cause and the discovery of disease-modifying treatments have remained elusive. Two key features of AD pathology are the aberrant deposition of amyloid beta (amyloid-β or Aβ) proteins in the brain parenchyma and Aβ toxicity in brain pericytes of the neurovascular unit/blood-brain barrier (NVU/BBB). This toxicity induces oxidative stress in pericytes and leads to capillary constriction. The interaction between pericytes and Aβ proteins results in the release of endothelin-1 in the pericytes. Endothelin-1 interacts with ET receptors to cause pericyte contraction. This pericyte-mediated constriction of brain capillaries can cause chronic hypoperfusion of the brain microvasculature, subsequently leading to the neurodegeneration and cognitive decline observed in AD patients. The interaction between Aβ proteins and brain pericytes is largely unknown and requires further investigation. This review provides an updated overview of the interaction between Aβ proteins with pericytes, one the most significant and often forgotten cellular components of the BBB and the inner blood-retinal barrier (IBRB). The IBRB has been shown to be a window into the central nervous system (CNS) that could allow the early diagnosis of AD pathology in the brain and the BBB using modern photonic imaging systems such as optical coherence tomography (OCT) and two-photon microscopy. In this review, I explore the regulation of Aβ proteins in the brain parenchyma, their role in AD pathobiology, and their association with pericyte function. This review discusses Aβ proteins and pericytes in the ocular compartment of AD patients as well as strategies to rescue or protect pericytes from the effects of Aβ proteins, or to replace them with healthy cells.
阿尔茨海默病(AD)是一种进行性神经退行性疾病,是痴呆症最常见的病因,在老年人群中尤为如此。尽管AD研究取得了进展,但其根本原因以及疾病修饰治疗方法的发现仍然难以捉摸。AD病理学的两个关键特征是淀粉样β蛋白(Aβ)在脑实质中的异常沉积以及神经血管单元/血脑屏障(NVU/BBB)的脑周细胞中的Aβ毒性。这种毒性会在周细胞中诱导氧化应激,并导致毛细血管收缩。周细胞与Aβ蛋白之间的相互作用会导致周细胞中内皮素-1的释放。内皮素-1与ET受体相互作用,导致周细胞收缩。这种由周细胞介导的脑毛细血管收缩可导致脑微血管慢性灌注不足,随后导致AD患者出现神经退行性变和认知能力下降。Aβ蛋白与脑周细胞之间的相互作用在很大程度上尚不清楚,需要进一步研究。本综述提供了Aβ蛋白与周细胞之间相互作用的最新概述,周细胞是血脑屏障和内血视网膜屏障(IBRB)最重要且常被遗忘的细胞成分之一。IBRB已被证明是进入中枢神经系统(CNS)的窗口,可使用光学相干断层扫描(OCT)和双光子显微镜等现代光子成像系统对大脑和血脑屏障中的AD病理学进行早期诊断。在本综述中,我探讨了脑实质中Aβ蛋白的调节、它们在AD病理生物学中的作用以及它们与周细胞功能的关联。本综述讨论了AD患者眼内的Aβ蛋白和周细胞,以及拯救或保护周细胞免受Aβ蛋白影响,或用健康细胞替代它们的策略。